Compared with other ablative therapies, stereotactic body radiotherapy might offer a ‘particularly advantageous option’ for ...

SBRT improved local progression-free survival over RFA in small recurrent HCC, particularly in tumors 2 cm or less. Among patients with single recurrent small hepatocellular carcinoma (HCC), ...

A short course of androgen deprivation therapy (ADT) added to stereotactic body radiotherapy (SBRT) halved the risk of ...

Phase 2 data support the use of SBRT in patients with CRPC who have 1-5 metastatic sites, according to researchers.

This approach was compared with the standard CT-guided SBRT, which typically requires larger treatment margins. The team found that patients receiving MRI-guided SBRT experienced significantly ...

The SBRT arm had significantly prolonged radiographic progression-free survival (rPFS) compared with patients who received enzalutamide plus ADT alone: 4.6 vs 2.3 years, for a significant 52% ...

Since the existence of the oligometastatic disease state was posited three decades ago,1 there has been interest in ...

While radiation therapy has been in use for more than 100 years, innovations including linear accelerators, imaging, and AI have made this treatment exceptionally targeted and highly effective.

The crossover of the bevacizumab and panitumumab survival curves in the PARADIGM study: A clue to time-related effects of bevacizumab on the risk of tumor progression. Risk of peritoneal recurrence ...

The UAB Department of Radiation Oncology has partnered with Varian to develop a three-day conference that discusses and demonstrates stereotactic radiation (SRS) and stereotactic body radiation (SBRT) ...